EyeWorld Weekly, May 3, 2024 – EyeWorld
➤ FDA clears fully autonomous, portable AI device for diabetic retinopathy screening ➤ Positive preliminary data for Phase 1/2 trial evaluating gene therapy treatment for X-linked retinoschisis ➤ Dosing in Phase 1/2 trial for allogenic cell therapy for corneal edema ➤ Dosing complete in trial assessing corneal edema therapy ➤ Phase 4 results for mydriasis product reported ➤ Collaboration seeks to commercialize Alzheimer’s detection through retinal imaging ➤ ASCRS news and events